Drug intelligence / Profile preview

chimeric antigen receptor T cells + aldesleukin

Development stage: Preclinical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

A combination immunotherapy consisting of genetically modified T cells (CAR-T cells) and aldesleukin (high-dose interleukin-2). CAR-T cells are engineered to express chimeric antigen receptors that recognize specific proteins on cancer cells, allowing them to bind to and destroy these cells. Aldesleukin is a cytokine therapy that activates the immune system. This combination leverages both the targeted killing ability of CAR-T cells and the immunomodulatory effects of aldesleukin to enhance antitumor activity.

Other names: in vitro tumor reactive, chimeric T cell receptor (CAR) gene-transduced PBL + aldesleukin

Targets

CD19 (B lymphocyte antigen CD19)IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on chimeric antigen receptor T cells + aldesleukin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chimeric antigen receptor T cells + aldesleukin.

Explore the full profile